Trial Profile
A Multi-national, Open-label, Dose Escalation Phase I/II study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs CYAD 01 (Primary)
- Indications Acute myeloid leukaemia; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Fallopian tube cancer; Haematological malignancies; Multiple myeloma; Myelodysplastic syndromes; Ovarian cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms THINK
- Sponsors Celyad Oncology
- 09 Feb 2023 Results presented in the Celyad Oncology Media Release.
- 09 Feb 2023 According to a Celyad Oncology media release, data from the haematological arm of the study was published were published in the journal The Lancet Haematology.
- 08 Dec 2020 Preliminary results of both THINK and DEPLETHINK clinical studies presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology